Altum Pharmaceuticals
Phase III Topical product to treat HPV infection (CIN 1&2) Phase III ready Product is an Interferon alpha 2-b incorporated in BiPhasix? Topical Formulation System to treat low grade CIN 1&2 to prevent cervical cancer. Currently there is no pharmaceuticals treatment for HPV infection. Two successful Phase II trials ($50 mil invested) have been completed and Altum will initiate the Phase III trials in 2018 Large untapped market Approximately 3 mil cases of CIN / year in the US Multi-billion market size for drugs for the primary treatment of CIN lesions